| Catalog No. | VK565056 |
|---|
| Species reactivity | SARS-CoV-2(2019-nCoV) |
|---|
| Applications | Research Grade Biosimilar |
|---|
| Host species | Human |
|---|
| Isotype | IgG1, lambda |
|---|
| Expression system | Mammalian Cells |
|---|
| Clonality | Monoclonal |
|---|
| Target | Spike glycoprotein, S glycoprotein, E2, Peplomer protein, Spike protein S1, Spike protein S2, Spike protein S2', S, 2 |
|---|
| Concentration | 2.9mg/ml |
|---|
| Endotoxin level | Please contact the lab for this information. |
|---|
| Purity | >95% purity as determined by SDS-PAGE. |
|---|
| Purification | Protein A/G, purified from cell culture supernatant. |
|---|
| Accession | P0DTC2 |
|---|
| Form | Liquid |
|---|
| Storage buffer | 0.01M PBS,pH7.4. |
|---|
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -472°C. |
|---|
| Alternate Names | REGN-10987,REGN10987,CAS:2415933-40-1 |
|---|
| Background | Imdevimab (REGN10987) is a human monoclonal antibody to target SARS-CoV-2 virus, which causes COVID-19. Imdevimab lacks efficacy against COVID-19 variants. Imdevimab can be used in combination with Casirivimab (HY-P99341), it reduces viral load and improves diseases. |
|---|
| Note | For research use only. Not for use in clinical or therapeutic applications. |
|---|
